These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21296791)

  • 1. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.
    Carrasco LR; Lee VJ; Chen MI; Matchar DB; Thompson JP; Cook AR
    J R Soc Interface; 2011 Sep; 8(62):1307-13. PubMed ID: 21296791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.
    Halder N; Kelso JK; Milne GJ
    BMC Infect Dis; 2014 May; 14():266. PubMed ID: 24884470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
    Newall AT; Wood JG; Oudin N; MacIntyre CR
    Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of optimal antiviral stockpile for a novel influenza pandemic.
    Kim S; Bin Seo Y; Lee J; Kim YS; Jung E
    J Infect Public Health; 2022 Jul; 15(7):720-725. PubMed ID: 35667304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigation of pandemic influenza: review of cost-effectiveness studies.
    Lugnér AK; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of stockpiling for an influenza pandemic.
    Dhankhar P; Dasbach EJ; Elbasha EH
    Lancet Infect Dis; 2009 Aug; 9(8):459-60. PubMed ID: 19628168
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories.
    Kelso JK; Halder N; Postma MJ; Milne GJ
    BMC Public Health; 2013 Mar; 13():211. PubMed ID: 23496898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.
    Postma MJ; Milne G; Nelson EA; Pyenson B; Basili M; Coker R; Oxford J; Garrison LP;
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1431-9. PubMed ID: 21133667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investment in antiviral drugs: a real options approach.
    Attema AE; Lugnér AK; Feenstra TL
    Health Econ; 2010 Oct; 19(10):1240-54. PubMed ID: 19816857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season.
    Meijer A; Lackenby A; Hay A; Zambon M
    Euro Surveill; 2007 Apr; 12(4):E3-4. PubMed ID: 17991386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis of pandemic influenza vaccination strategies in Singapore.
    Lee VJ; Tok MY; Chow VT; Phua KH; Ooi EE; Tambyah PA; Chen MI
    PLoS One; 2009 Sep; 4(9):e7108. PubMed ID: 19771173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
    Lugnér AK; Postma MJ
    Eur J Public Health; 2009 Oct; 19(5):516-20. PubMed ID: 19692550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza.
    Prosper O; Saucedo O; Thompson D; Torres-Garcia G; Wang X; Castillo-Chavez C
    Math Biosci Eng; 2011 Jan; 8(1):141-70. PubMed ID: 21361405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
    Pasquini-Descomps H; Brender N; Maradan D
    Value Health; 2017 Jun; 20(6):819-827. PubMed ID: 28577700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Push needed for pandemic planning.
    Dumiak M
    Bull World Health Organ; 2012 Nov; 90(11):800-1. PubMed ID: 23226890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare system cost evaluation of antiviral stockpiling for pandemic influenza preparedness.
    Li Y; Hsu EB; Links JM
    Biosecur Bioterror; 2010 Jun; 8(2):119-28. PubMed ID: 20569054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?
    Lokuge B; Drahos P; Neville W
    Med J Aust; 2006 Jan; 184(1):16-20. PubMed ID: 16398625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The WHO pandemic influenza preparedness framework: a milestone in global governance for health.
    Fidler DP; Gostin LO
    JAMA; 2011 Jul; 306(2):200-1. PubMed ID: 21750298
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis.
    Milne GJ; Halder N; Kelso JK
    PLoS One; 2013; 8(4):e61504. PubMed ID: 23585906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.